共查询到16条相似文献,搜索用时 156 毫秒
1.
2.
3.
目的:用meta分析方法评价不同剂量131I去除分化型甲状腺癌(DTC)术后残留甲状腺组织(简称清甲)的疗效。方法检索Cochrane图书馆、MEDLINE、OVID、Embase、EBSCO、SpringerLink 等数据库,初筛1980年1月至2013年8月有关高剂量(3700 MBq)与低剂量(1110 MBq)131I清甲治疗疗效的随机对照试验(RCT)文献。采用改良的Jadad量表对入选文献进行质量评价,用RveMan 5.1软件进行统计学分析。结果按照纳入及排除标准,共入选12篇RCT文献,共2290例患者。其中,高剂量组1069例、低剂量组1221例。按各文献报道的DTC患者术后131I清甲治疗成功标准,高剂量组与低剂量组首次清甲成功率之间的差异无统计学意义(Z=1.80,P>0.05);低、高剂量组分别采用重组人促甲状腺激素法(311例vs.288例)与激素撤退法(314例vs.284例)两种131I治疗准备方法时,两种方法首次清甲成功率之间的差异也无统计学意义(Z=0.98和0.33,P>0.05)。采用SF-36量表法分析DTC患者术后首次清甲治疗期间患者生活质量,两剂量组间差异也无统计学意义(Z=0.37,P>0.05),但高剂量组不良反应发生率明显高于低剂量组(Z=5.15,P<0.01),且所需隔离时间短。结论131I高剂量组与低剂量组以及两种不同准备方法的清甲治疗疗效基本一致,两剂量组治疗期间患者生存质量也无明显差别,但低剂量组较高剂量组的严重不良反应的发生率小。研究提示,对低风险DTC患者使用低剂量131I治疗可获得与高剂量131I治疗一致的清甲效果,同时可减少不良反应的发生。 相似文献
4.
影响分化型甲状腺癌术后^131I清甲治疗疗效的因素分析 总被引:12,自引:10,他引:2
目的回顾性分析分化型甲状腺癌(DTC)患者术后残余甲状腺组织^131I清除治疗疗效的影响因素。方法对80例DTC术后首次接受^131I清除甲状腺残余组织(简称清甲)治疗的临床资料进行回顾性分析。以小剂量^131I全身显像的方法作为^131I清甲疗效的判断依据,显像中甲状腺床位置未见放射性浓聚视为清甲成功。分别采用,检验和Binary Logistic多因素回归分析的方法,研究患者性别、年龄(〈45岁和≥45岁)、病理类型(乳头状癌和滤泡状癌)、甲状腺外有无转移、残余甲状腺质量(少、中、多)、24h甲状腺吸碘率(〈10%、10%~20%、〉20%)、血清甲状腺球蛋白(Tg,阴性和阳性)和促甲状腺激素(TSH,〈30、30~60、〉60mU/L)水平及^131I剂量(〈1850MBq、1850—3700MBq、〉3700MBq)对^131I清甲疗效的影响。结果80例DTC术后患者,一次^131I治疗成功清甲为58例,有效率为72.5%。经,检验,24h甲状腺吸碘率、残余甲状腺质量及^131I剂量3项变量对^131I清甲治疗的疗效产生影响,各组内疗效比较差异有统计学意义(x^2=8.892,9.528,15.085,P=0.012,0.009,0.001);而性别、年龄、病理类型、甲状腺外有无转移、血清Tg和TSH水平对^131I清甲治疗的疗效影响不显著,各组内疗效比较差异无统计学意义(x^2=0.486,0.051,0.322,0.010,0.006,2.575,P均〉0.05)。经Binary Logistic多因素回归分析,残余甲状腺质量(X1)和^131I剂量(X2)2项变量入选最终方程P=e^(-0.865-0.868X1+1.677X2)/[1-e^(-0.865-0.868X1+1.677X2)],Wald值分别为3.752和9.130,P值分别为0.049和0.003。结论DTC术后^131I清甲治疗的疗效主要取决于^131I治疗剂量和残余甲状腺的质量,与患者性别、年龄、病理类型、甲状腺外有无转移、血清Tg和TSH水平、甲状腺吸碘率无关。 相似文献
5.
6.
131I清除分化型甲状腺癌术后残留腺体的内照射吸收剂量与疗效的分析 总被引:1,自引:0,他引:1
目的 探讨131I清除DTC术后残留甲状腺组织(简称清甲)的内照射吸收剂量与疗效的相关性.方法 前瞻性分析2009年9月至2011年9月拟行清甲的72例DTC患者[男14例,女58例,年龄16~67(41±16)岁].在患者服用3.7 GBq 131I后采用连续显像法评估残留腺体的碘代动力学,利用超声测量残留腺体的质量,按照美国核医学会医用内照射剂量学委员会提出的内照射吸收剂量计算方法,计算残留腺体的吸收剂量.清甲治疗后6~9个月,判断疗效:若刺激状态下Tg<l μg/L及颈部超声检查提示甲状腺床区无腺体组织残留,判断为清甲成功.清甲成功与未成功者组间比较采用两样本t检验.结果 72例患者的残留腺体24h摄碘率为0.9%~6.3%, 131I有效半衰期为12.0~146.4 h,腺体质量为1.0~6.9g,吸收剂量为23~2 197 Gy,24 h吸收剂量率为0.5~8.1 Gy/h.43例清甲成功者与29例清甲未成功者残留腺体的吸收剂量分别为(363±148) Gy和(341±167) Gy,差异无统计学意义(£=15.097,P>0.05);24 h吸收剂量率分别为(3.7±2.1) Gy/h和(2.9±1.6) Gy/h,差异有统计学意义(t=7.908,P<0.05).结论 131I清甲残留腺体的吸收剂量率影响清甲疗效. 相似文献
7.
8.
9.
分化型甲状腺癌肺转移灶早期显影与^131I疗效关系分析 总被引:2,自引:1,他引:1
目的探讨DTC肺转移患者首次应用^131I清除甲状腺组织(简称清甲)时肺转移灶显像与^131I治疗效果的关系,及影响肺转移灶早期显影的因素。方法回顾分析1997至2009年41例DTC肺转移患者清甲治疗时肺转移灶显影情况,评价^131I治疗DTC肺转移疗效。疗效评价分临床治愈、好转和无效。前两者为治疗有效。采用SPSS11.5软件,对有效率、有无远处转移、显像特点进行,检验及交叉分类2×2列联表关联分析。结果41例患者中8例为临床治愈,18例好转,有效率63%(26/41),14例无效,1例患者死亡,无效率37%(15/41)。清甲治疗时肺部转移灶显影患者^131I治疗有效率76%(22/29),随访和重复治疗中显影患者^131I治疗有效率为33%(4/12),两者差异有统计学意义0,2=4.911,P=0.027);肺转移灶^131I摄取呈弥漫性或局灶性,两者间有效率分别为67%(12/18)和61%(14/23),差异无统计学意义(χ2=0.146,P=0.702);肺外有远处转移者^131I治疗DTC肺转移灶有效率为22%(2/9),无远处转移者有效率为75%(24/32),差异有统计学意义(χ2=6.312,P=0.012);83%(24/29)行甲状腺全切的患者在首次清甲治疗时即有肺转移灶显影,而行甲状腺部分切除患者中仅有42%(5/12),甲状腺手术方式与肺转移灶早期显影有相关性(r=0.411,P〈0.05);乳头状癌和滤泡状癌患者中首次清甲治疗时肺转移灶早期显影患者分别为72%(23/32)和6/9,病理分型和肺转移灶显影早晚无关(r=0.047,P〉0.05)。结论DTC肺转移患者清甲治疗时转移灶显影阳性、无肺外远处转移灶者的^131I疗效好。 相似文献
10.
11.
Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma 总被引:3,自引:0,他引:3
Arslan N Ilgan S Serdengecti M Ozguven MA Bayhan H Okuyucu K Gulec SA 《Nuclear medicine communications》2001,22(9):1021-1027
The aims of this study were to evaluate the efficacy of an empirically determined "fixed" high ablative dose of radioiodine ((131)I) therapy and to determine the utility of ultrasonography (US) in dose determination. A retrospective analysis was performed of 242 thyroid cancer cases treated with "fixed" high-dose (131)I for ablation of thyroid remnants without a pre-ablative (131)I diagnostic scintigraphy or radioiodine uptake study. Treatment doses ranged from 1850 MBq (50 mCi) to 7.4 GBq (200 mCi). The selection of the treatment dose was based on the surgical and pathological findings as well as the remnant thyroid volume calculated by US. A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Successful ablation was obtained in 218 of the 242 patients (90%). In 162 of the 218 patients (74.3%), successful ablation was achieved after a single (131)I treatment. The remnant thyroid volume calculated by US was significantly different (P=0.04) between those who were successfully ablated and those who were not. The total (131)I dose needed for successful ablation was significantly higher in males (P=0.003). Patients with higher post-operative thyroglobulin (Tgb) levels and patients with a higher stage of disease required higher doses (P=0.036 and P=0.021 respectively). Serum Tgb levels were under 10 ng.ml(-1) in 220 of the 242 patients (90%) following radioiodine ablation while not receiving L-thyroxine suppression. Nineteen patients (7.8%) showed metastases on post-therapy scan and successful treatment was achieved in 11 of 19 (57.8%). Four of the 19 patients with distant metastases (revealed on post-treatment scan) were found to have been given a treatment dose of less than 200 mCi based on the proposed empirical approach. These results indicate that "fixed" high-dose (131)I treatment is clinically feasible with an acceptable dose underestimation rate, and the utilization of US in the determination of the thyroid remnant volume provides more accurate and reproducible results. 相似文献
12.
131I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和131I-全身显像的意义 总被引:1,自引:0,他引:1
目的探讨分化型甲状腺癌转移灶治疗中131I-全身显像(131I-WBS)和甲状腺球蛋白(Tg)测定的意义。方法39例分化型甲状腺癌患者术后4~6周用131I行首次清除残余甲状腺治疗,3~6个月后重复治疗,治疗中131I-WBS和Tg测定同期完成。结果在首次清除残余甲状腺治疗时显像发现淋巴、肺及骨转移灶有11例,其余转移灶于重复治疗时发现。131I治疗分化型甲状腺癌转移灶,以淋巴转移效果最好,肺转移次之,骨转移最差。有8例患者(20.5%)Tg测定与131I-WBS不符。结论131I治疗分化型甲状腺癌转移灶效果好,患者存活率高;131I-WBS和Tg测定在分化型甲状腺癌随访中应联合应用,互相补充。 相似文献
13.
目的 评估分化型甲状腺癌(DTC)患者^131I治疗后体内残留放射性活度.方法 本研究共纳入了35例DTC患者,分为“清甲”(20例)与“清灶”(15例)组,分别于服^13I后2、6、24、48、72 h进行^131I全身显像及1m处当量剂量率的测定,以2h时显像计数和活度作为总计数和总活度.根据各时间点显像计数与2h的显像计数比值间接估算体内残留放射性活度,并估算患者体内残留放射性活度达到400 MBq时的1m处当量剂量率.统计学分析采用直线相关与回归分析.结果 “清甲”组服^131I后2、6、24、48、72 h体内残留^131I活度占服^131I总活度的百分比分别为99%±4%、86%±6%、35%±10%、12%±8%、7%±8%, “清灶”组分别为99%±1%、91%±7%、47%±17%、11%±9%、4%±6%. “清甲”组服^131I后2、6、24、48、72 h的1m处当量剂量率分别为(157±37)、(120±36)、(35±13)、(11±9)、(9±11)μSv/h,“清灶”组分别为(234±43)、(186±51)、(49±20)、(12±11)、(4±6)μSv/h.体内残留的放射性活度与1m处当量剂量率呈正相关(r=0.87,P<0.001).“清甲”与“清灶”组服^131I后48、72 h体内残留放射性活度分别为(432±292)、(265±281) MBq及(731±701)、(277±470) MBq,对应的1m处当量剂量率为8~ 11 μSv/h.结论 DTC患者服^131I后48~72 h体内残留放射性活度达到国家标准规定的400 MBq时,即DTC患者1m处当量剂量率达到8~11 μSv/h时方可出院. 相似文献
14.
不同剂量首次131I去除甲状腺术后残留组织疗效比较 总被引:2,自引:0,他引:2
目的 回顾分析343例DTC病例,比较不同剂量首次131I去除甲状腺术后残留组织(RRA)疗效,并分析影响疗效的因素.方法 343例DTC患者行甲状腺全切术或近全切术,术后经影像学检查无局部或远处转移.以首次131I剂量将343例患者分为3组:A组101例,剂量为1850 ~2220 MBq;B组103例,剂量为2590~2960 MBq;C组139例,剂量为3330~3700 MBq.RRA后随访6~12个月.判断RRA成功标准:(1)131I全身扫描甲状腺床未见放射性摄取;(2) TSH刺激状态的Tg<10 μg/L.应用SPSS 15.0软件对数据进行x2检验和logistic回归分析.结果 (1)343例患者RRA成功率63%( 215/343);(2)A、B和C组成功率分别为59%( 60/101)、64%( 66/103)和64%(89/139),3组疗效差异无统计学意义(x2=0.657,P=0.720);(3)单因素分析:筛选出性别(P=0.030)、手术方式(P<0.01)、手术次数(P=0.004)、治疗前TSH(P =0.019)、治疗前Tg水平(P<0.01)为有关因素,剔除年龄(P=0.420)、病理类型(P =0.585)、淋巴结转移(P =0.858)、多灶(P=0.365)、TNM分期(P =0.388)和剂量(P=0.733)等无关因素,将有关因素进行logistic回归分析,手术方式(P<0.01)和治疗前Tg水平(P<0.O1)是影响RRA疗效的因素.结论 DTC患者甲状腺全切或近全切术后,小剂量1850 ~ 2220 MBq RRA与大剂量3330~ 3700 MBq RRA疗效相同.术式和治疗前Tg水平是影响RRA成功的重要因素. 相似文献
15.
Edward B Silberstein 《Journal of nuclear medicine》2007,48(7):1043-1046
Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I. The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form of cell damage from the diagnostic dosage of the radionuclide. Stunning could potentially reduce the therapeutic efficacy of (131)I given to ablate a post-thyroidectomy remnant. This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our Thyroid Cancer Center reduce the efficacy of (131)I given for remnant ablation. METHODS: Fifty patients with nonmetastatic papillary or follicular carcinoma of the thyroid received total thyroidectomy; this was followed by thyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microIU/mL. They were divided prospectively into 2 groups. Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by thyroid remnant ablation with 3.7 GBq of (131)I. Group 2 had empiric ablation with the same 3.7-GBq (131)I dosage, but the preceding diagnostic scan was performed with 74 MBq of (131)I. Comparisons of equivalence of the 2 population samples and of the post-ablation outcomes were evaluated by chi(2) analysis. Successful ablation required a negative follow-up thyroid scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies. RESULTS: There was no significant difference between the 2 groups demographically, in tumor burden or stage, or in the post-thyroidectomy ablation rate (group 1, 81%; group 2, 74%; P > 0.05). CONCLUSION: If thyroid remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging. 相似文献
16.
We present data on repeated iodine-131 whole body scans ((131)I-WBS) in differentiated thyroid cancer patients (DTC) after surgery and (131)I remnant ablation and on increased thyroglobulin (Tg) with negative (131)I-WBS, in a retrospective study at our hospital. A total of 106 patients (91 female and 15 male) treated with (131)I for DTC met the inclusion criteria. The mean age of the patients was 45 years, age range 16-81 years. A total of 101 patients had complete 24 months follow-up following (131)I remnant ablation treatment. The mean (131)I dose administered after the first 6 months of follow- up was 3GBq while mean total dose was 4.9GBq, range 1.1-7.4GBq. Our results showed that at the end of the first 6 months post treatment, 58/101 patients had a negative (131)I-WBS. By the end of the 4th (131)I treatment at 24th months, the remaining 43 patients became negative for (131)I-WBS. We found increased Tg and negative (131)I-WBS in 2 of the 101 patients at the 24th months examination the so called Tg elevated negative (131)I-WBS (TENIS syndrome). The possible explanation of this syndrome is discussed. In conclusion, our study in DTC operated patients does not support the use of repeated diagnostic (131)I-WBS after an undetectable Tg because we found no Tg rebound in patients with negative (131)I-WBS, after 24 months of follow-up with serial measurements of Tg on and of suppression with L thyroxine. 相似文献